NICE changes its mind on Janssen’s Erleada
Prostate cancer therapy now recommended for two indications within its marketing authorisation
Read More
Tag: Erleada
Janssen’s Erleada maintains quality of life for prostate cancer patients
New patient-reported outcomes data also shows Erleada did not worsen side effect burden
Read More
NICE turns down Janssen’s Erleada
Cost-effectiveness estimates have fallen above the threshold because of uncertain trial evidence
Read More
EU licence granted for Erleada in prostate cancer
Janssen’s new treatment for prostate cancer Erleada has been licensed by the European Commission.
Read More
CHMP backs four medicines for approval
Four medicines have taken a giant leap closer to approval having won the backing of the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).
Read More
- US study reveals interferon combinations cause lupus symptoms and affect treatment
- NIHR and TJBCM announce new funding initiative for novel brain tumour research
- UKHSA and ICL confirm variant which plays key role in global surge of Strep A infections
- Study reveals heart failure device could monitor patients and prevent hospitalisation
- MIT’s new MRI brain light-detecting technique could support brain cell studies
